Charting the Managed Access Program Landscape

A Regulatory and Logistical Overview

Many patients with serious or life-threatening diseases cannot wait the years it can take for an investigational product to move from the lab to the pharmacy shelf.

Even with recent tendencies towards accelerated marketing approval, new treatments do not make it to market fast enough. Managed Access Programs are one solution for early access to investigational products. 

While regulators and developers generally prefer that patients gain access to investigational drugs by participating in clinical trials, patients are not always eligible to take part. An increasingly common solution is to grant compassionate use through Managed Access Programs (MAPs).   

Also known as expanded access, compassionate use, and named patient programs, this approach differs significantly from the traditional drug development process and brings with it new regulatory and operational complexities. Without the right knowledge, resources, processes, and tools, clinical teams can be caught off guard by the demands of a MAP. 

To help you prepare, ICON is writing a series of whitepapers to serve as a primer on Managed Access Programs. The first will explain how MAPs differ amongst themselves globally and from RCTs, when they are appropriate, how they are regulated around the world, and how to plan for them.

Pre-order Whitepaper

Pre-order your copy of the first MAP whitepaper. Get the insights you need to understand and plan for the regulatory and operational challenges in managed access programs.